<DOC>
	<DOC>NCT02462005</DOC>
	<brief_summary>A total of up to 250 patients from an all-comers patient population with infrainguinal atherosclerotic disease who are implanted or scheduled for an implant with a Ranger Drug coated balloon. Interim analysis will be carried out for every 50 subjects enrolled.</brief_summary>
	<brief_title>Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter. All Comers Registry.</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Age â‰¥ 18 years. Patient must be willing to sign a a patient informed consent form. Patient with de novo, restenotic or reoccluded lesions in the infrainguinal .arteries implanted or scheduled for an implant with a Ranger Drug coated balloon. Target vessel reference diameter 2.5 to 8 mm. Subjects pregnant or planning to become pregnant during the course of the study. Life expectancy of less than 1 year. Known allergy to concomitant medication, contrast agents (that cannot be medically managed), antiplatelet, anticoagulant or thrombolytic medications. Subject enrolled in another study that has not reached its primary endpoint at the time of enrolment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>